Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: A pilot study

Archives of Surgery

Volumn 145, Issue 3, 2010, Pages 233-238

  Orditura, Michele ^a   De Vita, Ferdinando ^a   Muto, Paolo ^b   Vitiello, Fabiana ^a   Murino, Paola ^b   Lieto, Eva ^a   Vecchione, Loredana ^a   Romano, Anna ^a   Martinelli, Erika ^a   Renda, Andrea ^c   Ferraraccio, Francesca ^a   Del Genio, Alberto ^a   Ciardiello, Fortunato ^a   Galizia, Gennaro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Radioth Ascalesi Hosp   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER DISEASE; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SICKNESS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 77951084425     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2010.2     Document Type: Article

References (36)

1. Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol. 2002;12(2):111-127.
2. Sakamoto J, Morita S, Kodera Y, Rahman M, Nakao A. Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives. Cancer Chemother Pharmacol. 2004;54(suppl 1):S25-S31. (Pubitemid 39517745)
3. Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15(1):69-79.
4. Yang SH, Zhang YC, Yang KH, et al. An evidence-based medicine review of lymphadenectomy extent for gastric cancer. Am J Surg. 2009;197(2):246-251.
5. Sasako M, Sano T, Yamamoto S, et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453-462.
6. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14(2):317-328.
7. Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg. 2006;243(1):74-81. (Pubitemid 43054057)
8. Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol. 2007;14(10):2687-2690. (Pubitemid 47460625)
9. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach. N Engl J Med. 2001;345(10):725-730.
10. Kollmannsberger C, Budach W, Stahl M, et al. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol. 2005;16(8):1326- 1333. (Pubitemid 41158478)
11. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol. 2006;12(4):603-607.
12. Leong T, Michael M, Foo K, et al. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimen before and after chemoradiation. Br J Cancer. 2003;89(8):1433-1438. (Pubitemid 37390854)
13. Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. In: Greene FL, ed. Stomach. 6th ed. New York, NY: Springer-Verlag; 2002:99-106.
14. Marchet A, Mocellin S, Ambrosi A, et al; Italian Research Group for Gastric Cancer Study (GIRCG). The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. Eur J Surg Oncol. 2008;34(2):159-165.
15. NCI toxicity. http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/NCI- toxicity-table.pdf.
16. Caussanel JP, Levi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst. 1990;82(12):1046-1050. (Pubitemid 20204976)
17. Vecchione L, Orditura M, Ciardiello F, De Vita F. Novel investigational drugs for gastric cancer. Expert Opin Investig Drugs. 2009;18(7):945-955.
18. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002;13(2):299-307. (Pubitemid 34704984)
19. Cascinu S, Labianca R, Barone C, et al; Italian Group for the Study of Digestive Tract Cancer. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst. 2007;99(8):601-607.
20. Nitti D, Wils J, Dos Santos JG, et al; EORTC GI Group; ICCG. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer: a combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 2006;17(2):262-269. (Pubitemid 43160116)
21. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11(8):1441-1447. (Pubitemid 23228247)
22. De Vita F, Giuliani F, Orditura M, et al; Gruppo Oncologico Italia Meridionale. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 study). Ann Oncol. 2007;18(8):1354-1358. (Pubitemid 47305009)
23. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer. 1999;35(7):1059-1064.
24. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials: a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000;11(7):837-843.
25. Hu JK, Chen ZX, Zhou ZG, et al. Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol. 2002;8(6):1023-1028. (Pubitemid 35446414)
26. Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analysis. Tumori. 2002;88(1):21-27. (Pubitemid 34269794)
27. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analyses. Eur J Surg. 2002;168(11):597-608. (Pubitemid 36355892)
28. Bajetta E, Pozzo C, Di Bartolomeo M, Mariani L, Barone C, Nitti D. Significant survival benefit of adjuvant chemotherapy in gastric cancer: results of individual patient data based meta-analysis of randomized trials. Paper presented at: 10th Italian National Congress of Medical Oncology; October 11-14, 2008; Verona, Italy.
29. Sasako M. Adjuvant chemotherapy with 5-FU or regimens including oral fluoropyrimidine for curable gastric cancer. Gastric Cancer. 2009;12(suppl 1):10-15.
30. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in respectable gastric cancer: five-year follow-up. Lancet. 1994;343(8909):1309-1312. (Pubitemid 2082066)
31. Moertel CG, Childs DS, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol. 1984;2(11):1249-1254.
32. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92(9):1644-1649. (Pubitemid 40762627)
33. Louvet C, Andrè T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20(23):4543-4548. (Pubitemid 35407422)
34. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22(4):658-663. (Pubitemid 41102130)
35. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 2000;88(4):921-932.
36. Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol. 2002;9(1):27-34. (Pubitemid 34262894)